Skip to search formSkip to main contentSkip to account menu

azimilide

Known as: 2,4-Imidazolidinedione, 1-(((5-(4-chlorophenyl)-2-furanyl)methylene)amino)-3-(4-(4-methyl-1-piperazinyl)butyl)-, azmilide 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (4)

Anti-Arrhythmia AgentsCalcium Channel BlockersHydantoinsPiperazines

Narrower (2)

NE 10064azimilide dihydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
A mechanism underlying compound-induced voltage shift in the current activation of hERG by antiarrhythmic agents.
2007
2007
QT Interval Prolongation and Torsades De Pointes Due to a Coadministration of Ciprofloxacin and Azimilide in a Patient with Implantable Cardioverter–Defibrillator
The presented case report describes a male patient with an implanted cardioverter–defibrillator (ICD) in whom a coadministration… 
2006
2006
Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro.
AIMS To compare the electrophysiological and antiarrhythmic effects of AZD7009, azimilide, and AVE0118 in the acutely dilated… 
2005
2005
Assessment of the Proarrhythmic Potential of the Novel Antiarrhythmic Agent AZD7009 and Dofetilide in Experimental Models of Torsades De Pointes
Background: This study examined the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide. 
Review
2004
Review
2004
Trials of New Antiarrhythmic Drugs for Maintenance of Sinus Rhythm in Patients with Atrial Fibrillation
Despite the recent results of the AFFIRM trail showing that either strategy of rate control or rhythm control is acceptable… 
Review
2002
Review
2002
Recent advances in arrhythmia therapy: treatment and prevention of atrial fibrillation.
  • A. Bril
  • Current opinion in pharmacology (Print)
  • 2002
  • Corpus ID: 8647746
1999
1999
Azimilide Decreases Defibrillation Voltage Requirements and Increases Spatial Organization During Ventricular Fibrillation
Introduction. Drugs with class III antiarrhythmic properties generally decrease defibrillation threshold (DFT). However, the… 
1999
1999
Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing
This study assessed steady‐state azimilide pharmacokinetics and pharmacodynamics in 119 healthy male and female volunteers… 
1999
1999
The class III effect of azimilide is not associated with reverse use-dependence in open-chest dogs.
Certain class III antiarrhythmic agents manifest loss of effect at short cycle lengths (CLs). This effect may limit their… 
1997
1997
Comparison of the Rate‐Dependent Properties of the Class III Antiarrhythmic Agents Azimilide (NE‐10064) and E‐4031
Rate Dependence of Azimilide and E‐4031. Introduction: Reverse rate‐dependence, a lessening in Class III antiarrhythmic agent… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)